Apogee Therapeutics, Inc.
APGE
$68.50
$1.732.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -255.84M | -253.67M | -237.67M | -205.39M | -182.15M |
| Total Depreciation and Amortization | 1.42M | 1.09M | 730.00K | 367.00K | 189.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 42.45M | 36.69M | 28.21M | 20.65M | 12.79M |
| Change in Net Operating Assets | -15.48M | -16.58M | -12.02M | -3.64M | -2.00M |
| Cash from Operations | -227.45M | -232.48M | -220.74M | -188.02M | -171.17M |
| Capital Expenditure | -5.15M | -5.08M | -5.84M | -5.12M | -1.15M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -174.43M | 160.50M | -3.07M | -230.62M | -299.31M |
| Cash from Investing | -179.57M | 155.42M | -8.90M | -235.74M | -300.46M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 396.49M | 65.90M | 46.54M | 45.36M | 495.26M |
| Repurchase of Common Stock | -- | -- | -- | -150.00K | -150.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 396.49M | 65.90M | 46.54M | 45.21M | 495.11M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.53M | -11.16M | -183.11M | -378.54M | 23.47M |